Ascendis Pharma (NasdaqGS:ASND) opened 2026 with Q1 revenue of €246.6 million and Basic EPS of €10.2, supported by net income excluding extra items of €629.3 million. The company has seen quarterly revenue move from €173.9 million in Q4 2024 to €247.5 million in Q4 2025 and €246.6 million in Q1 2026, while Basic EPS shifted from a loss of €0.64 in Q4 2024 to a loss of €0.55 in Q4 2025 before turning to a €10.2 profit in the latest quarter. This points to a very large improvement in reported margins that investors will want to dissect in terms of quality and durability.

See our full analysis for Ascendis Pharma.

With the headline numbers in place, the next step is to see how this sharp earnings shift lines up with the prevailing growth and risk narratives that investors have been following around Ascendis Pharma.

Trailing €495.9m profit changes the multi year picture

• On a trailing 12 month basis, Ascendis Pharma moved from a net loss of €378.1 million in Q4 2024 to net income of €495.9 million by Q1 2026, with Basic EPS moving from a loss of €6.53 to a profit of €8.12 over the same window.
• What stands out for the more bullish narrative is that this new profitability sits alongside forecast earnings growth of about 28.7% per year. Yet the data also highlight a high proportion of non cash earnings, so:
  • The sharp swing from a Q1 2025 loss of €341.7 million on a trailing basis to a €495.9 million profit is heavily supportive of the bullish focus on earnings growth, because it shows profitability across a full year rather than just a single quarter.
  • At the same time, the flag that operating cash flow does not fully cover debt means those bullish expectations are partly tested by how much of the €629.3 million Q1 2026 net income excluding extra items actually turns into cash.

Investors who want to see how this profit swing fits into broader growth, risk, and valuation views can tap into a wider set of community perspectives through the Curious how numbers become stories that shape markets? Explore Community Narratives.

Revenue at €865.8m supports the growth story

• Over the last 12 months, total revenue reached €865.8 million, compared with €363.6 million in the prior trailing 12 month period, and forecasts in the data point to revenue growth of about 25% per year.
• Supporters of the bullish view often focus on this revenue profile plus the reported 17.7% per year earnings growth over five years, and the numbers here give that story some weight while also adding useful context:
  • The move from €368.7 million trailing revenue at Q1 2025 to €865.8 million by Q1 2026 gives concrete backing to growth focused arguments, because it shows a much larger top line supporting the latest profit figures.
  • At the same time, the fact that multi year averages are harder to interpret now that the company has only recently become profitable is a reminder that longer term trend claims need to be read with care alongside these revenue jumps.

P/E of 26.1x and €829.64 DCF fair value send mixed valuation signals

• The stock trades on a trailing P/E of 26.1x, compared with a US Biotechs industry average of 17.8x and a peer average of 12.6x, while the DCF fair value in the data is €829.64 per share against a current share price of €246.14.
• Critics who take a more cautious view often point to the premium P/E and the fact that operating cash flow does not fully cover debt, but here the figures cut both ways:
  • The higher P/E multiple versus peers and industry gives bearish arguments some footing, because it shows investors are already paying more per euro of trailing earnings than for many alternatives.
  • However, the gap between the €246.14 share price and the DCF fair value of €829.64 challenges a simple bearish valuation call, as it suggests that at least one modelled view of intrinsic value is much higher than where the stock currently trades.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Ascendis Pharma's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With the mix of strong recent figures and clear pressure points, sentiment is split. Check the underlying data, stress test your own thesis, and weigh both the 3 key rewards and 3 important warning signs.

See What Else Is Out There

The premium P/E, high reliance on non cash earnings and pressure around debt coverage suggest the current profile may not suit more risk aware investors.

If you want businesses where profit quality and balance sheet strength are more central, check out the solid balance sheet and fundamentals stocks screener (44 results) to quickly compare alternatives built for resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.